{"disease":{"id":"fabry-s-disease","name":"Fabry's disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"agalsidase-beta","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabrazyme","generic_name":"AGALSIDASE BETA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":59,"revenue":"1000","mechanism":"Fabrazyme works by replacing the deficient enzyme alpha-Gal A to break down and remove toxic globotriaosylceramide."},{"drug_id":"pegunigalsidase-alfa","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elfabrio","generic_name":"PEGUNIGALSIDASE ALFA","company_name":"Chiesi Farmaceutici S.P.A","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Elfabrio works by reducing the accumulation of a specific lipid in the body."},{"drug_id":"replagal","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Replagal","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"agalsidase-alfa","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Replagal","generic_name":"AGALSIDASE ALFA","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"migalastat","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Galafold","generic_name":"MIGALASTAT","company_name":"Amicus Therap Us","drug_phase":"marketed","molecular_target":"Alpha-galactosidase A","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Galafold stabilizes the alpha-galactosidase A enzyme to treat Fabry's disease."},{"drug_id":"agalsidase","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"agalsidase","company_name":"Amicus Therapeutics","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pegunigalsidase-alfa-iwxj","indication_name":"Fabry's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ELFABRIO","generic_name":"PEGUNIGALSIDASE ALFA-IWXJ","company_name":"CHIESI FARMACEUTICI SPA","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT07336394","title":"Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT02450604","title":"Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":776,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06813443","title":"Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03321604","title":"Kidney Information Network for Disease Research and Education","phase":"","overall_status":"TERMINATED","enrollment_count":338,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT00001491","title":"Analysis of the Nervous System in Patients With Fabry's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04943991","title":"Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wuerzburg University Hospital","has_results":false},{"nct_id":"NCT04758130","title":"Getting Global Rare Disease Insights Through Technology Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.A.G.I.C. Clinic LTD","has_results":false},{"nct_id":"NCT04043273","title":"Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences","phase":"","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Amicus Therapeutics France SAS","has_results":false},{"nct_id":"NCT06325488","title":"Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Caroline Michaela Kistorp","has_results":false},{"nct_id":"NCT06776419","title":"the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease","phase":"","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Caroline Michaela Kistorp","has_results":false},{"nct_id":"NCT05413876","title":"Fabry Exercise Intolerance Study","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT03838237","title":"Effect of Migalastat on Cardiac Involvement in Fabry Disease","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Ospedale San Donato","has_results":false},{"nct_id":"NCT06019728","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT04040049","title":"A Fabry Disease Gene Therapy Study","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT04455230","title":"A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT04189601","title":"Complement Activation in the Lysosomal Storage Disorders","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Melbourne Health","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}